Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
81.83
+0.67 (0.83%)
Aug 22, 2025, 4:00 PM - Market closed
Edwards Lifesciences Stock Forecast
Stock Price Forecast
The 20 analysts that cover Edwards Lifesciences stock have a consensus rating of "Buy" and an average price target of $85.2, which forecasts a 4.12% increase in the stock price over the next year. The lowest target is $60 and the highest is $95.
Price Target: $85.2 (+4.12%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Edwards Lifesciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 5 | 5 | 5 | 6 | 6 |
| Hold | 10 | 9 | 9 | 9 | 9 | 8 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 20 | 20 | 20 | 21 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $84 → $88 | Buy | Maintains | $84 → $88 | +7.54% | Aug 7, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $80 → $85 | Hold | Maintains | $80 → $85 | +3.87% | Jul 25, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $75 → $81 | Hold | Maintains | $75 → $81 | -1.01% | Jul 25, 2025 |
| Mizuho | Mizuho | Buy Maintains $87 → $95 | Buy | Maintains | $87 → $95 | +16.09% | Jul 25, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $81 → $82 | Hold | Maintains | $81 → $82 | +0.21% | Jul 25, 2025 |
Financial Forecast
Revenue This Year
6.15B
from 5.44B
Increased by 12.97%
Revenue Next Year
6.74B
from 6.15B
Increased by 9.65%
EPS This Year
2.56
from 6.97
Decreased by -63.31%
EPS Next Year
2.85
from 2.56
Increased by 11.53%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.3B | 7.1B | 7.9B | ||
| Avg | 6.1B | 6.7B | 7.4B | ||
| Low | 5.7B | 6.2B | 6.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.6% | 15.2% | 16.9% | ||
| Avg | 13.0% | 9.7% | 10.2% | ||
| Low | 4.6% | 0.1% | -0.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.93 | 3.22 | 3.45 | ||
| Avg | 2.56 | 2.85 | 3.18 | ||
| Low | 2.38 | 2.56 | 2.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -58.0% | 26.1% | 21.1% | ||
| Avg | -63.3% | 11.5% | 11.7% | ||
| Low | -65.8% | 0.1% | -5.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.